Paradigm Biocapital Advisors as of March 31, 2025
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 27 positions in its portfolio as reported in the March 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 17.1 | $374M | 5.3M | 70.92 | |
| Arcellx Common Stock (ACLX) | 13.5 | $295M | 4.5M | 65.60 | |
| Revolution Medicines (RVMD) | 10.0 | $219M | 6.2M | 35.36 | |
| Beigene Sponsored Ads (ONC) | 8.3 | $181M | 666k | 272.17 | |
| Merus N V (MRUS) | 6.5 | $142M | 3.4M | 42.09 | |
| Tarsus Pharmaceuticals (TARS) | 6.1 | $134M | 2.6M | 51.37 | |
| Edgewise Therapeutics Call Option (EWTX) | 4.9 | $108M | 4.9M | 22.00 | |
| Janux Therapeutics (JANX) | 4.1 | $90M | 3.3M | 27.00 | |
| Crinetics Pharmaceuticals In (CRNX) | 3.0 | $65M | 1.9M | 33.54 | |
| Vaxcyte (PCVX) | 2.9 | $64M | 1.7M | 37.76 | |
| Disc Medicine (IRON) | 2.8 | $60M | 1.2M | 49.64 | |
| Cogent Biosciences (COGT) | 2.5 | $54M | 9.0M | 5.99 | |
| Lenz Therapeutics (LENZ) | 1.8 | $39M | 1.5M | 25.71 | |
| Apogee Therapeutics (APGE) | 1.6 | $36M | 962k | 37.36 | |
| Argenx Se Sponsored Adr (ARGX) | 1.6 | $35M | 60k | 591.87 | |
| Cytokinetics Com New (CYTK) | 1.6 | $35M | 859k | 40.19 | |
| Insmed Com Par $.01 (INSM) | 1.6 | $34M | 451k | 76.29 | |
| Spyre Therapeutics Com New (SYRE) | 1.6 | $34M | 2.1M | 16.14 | |
| Mestera (MTSR) | 1.5 | $32M | 1.2M | 27.22 | |
| Miragen Therapeutics (VRDN) | 1.3 | $28M | 2.1M | 13.48 | |
| Olema Pharmaceuticals (OLMA) | 1.2 | $25M | 6.7M | 3.76 | |
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.1 | $25M | 627k | 39.07 | |
| Arcutis Biotherapeutics (ARQT) | 1.0 | $23M | 1.5M | 15.64 | |
| Y Mabs Therapeutics | 0.9 | $19M | 4.2M | 4.43 | |
| Erasca (ERAS) | 0.7 | $15M | 11M | 1.37 | |
| Ocular Therapeutix (OCUL) | 0.4 | $9.6M | 1.3M | 7.33 | |
| Immatics SHS (IMTX) | 0.4 | $8.6M | 1.9M | 4.51 |
